SCHEMBL3236221

SCHEMBL3236221

Cc1ccc(Cl)c(C)c1C(=O)NC(c1ccccc1)C(C)(C)N1CCCC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.37
SLC6A9 P48067 3/20 0.37
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 3/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
TP53 P04637 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
APAF1 O14727 1/20 0.36
MAPK1 P28482 1/20 0.36
MCL1 Q07820 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
OPRK1 P41145 1/20 0.35
LIPG Q9Y5X9 1/20 0.34
KMT2A Q03164 1/20 0.34
RAB9A P51151 1/20 0.34
CCR5 P51681 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3241715 0.88 SLC6A9 (0.42) LMNASLC6A9ALDH1A1SMN1; SMN2HTT
SCHEMBL3243734 0.86 SLC6A9 (0.48) LMNASLC6A9ALDH1A1SMN1; SMN2HPGD
SCHEMBL3238301 0.85 SLC6A9 (0.47) LMNASLC6A9ALDH1A1HPGDL3MBTL1
SCHEMBL3241373 0.84 ALDH1A1 (0.39) LMNASLC6A9ALDH1A1SMN1; SMN2HTT
SCHEMBL3239948 0.84 KMT2A (0.38) LMNAALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL3230685 0.83 ALDH1A1 (0.44) LMNASLC6A9ALDH1A1SMN1; SMN2HTT
SCHEMBL3241801 0.83 LMNA (0.40) LMNASLC6A9ALDH1A1MAPK1OPRK1
SCHEMBL3233025 0.82 SLC6A9 (0.39) LMNASLC6A9ALDH1A1SMN1; SMN2HPGD
SCHEMBL3235815 0.82 TAS1R3 (0.43) LMNAALDH1A1MAPTTSHRKMT2A
SCHEMBL3234680 0.81 SLC6A9 (0.42) SLC6A9HPGDL3MBTL1KMT2ACCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 LMNA 4449/4885SLC6A9 13/4885ALDH1A1 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.